Updated Meta-Analysis Reinforces Short-Term Efficacy of Modafinil for Excessive Daytime Sleepiness in Narcolepsy

An updated systematic review and meta-analysis of randomized clinical trials reinforces the role of modafinil as an effective short-term treatment for excessive daytime sleepiness (EDS) in narcolepsy, while also highlighting a notable lack of contemporary randomized evidence in the field.¹

In the analysis, study authors, including lead author Govind Singh Mann, a resident at the University of Kansas Department of Neurology, identified 9 eligible studies through a comprehensive search of major databases, with 5 randomized controlled trials comprising 997 adult patients included in the quantitative meta-analysis. Across these studies, modafinil demonstrated statistically significant improvements in both objective and subjective measures of wakefulness compared with placebo.

On the Maintenance of Wakefulness Test (MWT), modafinil-treated patients showed a mean increase of 3.56 minutes (95% CI, 2.25–4.86; P <.00001), reflecting improved ability to sustain wakefulness. Similarly, treatment was associated with a reduction of 3.34 points on the Epworth Sleepiness Scale (ESS) (95% CI, –4.13 to –2.56; P <.00001), indicating a clinically meaningful decrease in perceived daytime sleepiness.

These findings were consistent across sensitivity analyses, which reduced heterogeneity without materially altering effect estimates, supporting the robustness of modafinil’s benefit across study designs and dosing regimens.

Importantly, the magnitude of improvement observed in MWT is considered clinically relevant. Prior research has suggested that gains of approximately 2 to 3 minutes on MWT may translate into meaningful improvements in daily functioning and safety, including driving performance. In this context, the observed 3.56-minute increase further supports modafinil’s utility as a wake-promoting agent.

The analysis also provides insight into dosing considerations. Variability across studies, including total daily doses ranging from 200 mg to 600 mg and use of split-dose versus once-daily regimens, contributed to moderate heterogeneity (I² = 67% for MWT). However, the overall treatment effect remained consistent even after excluding higher-dose studies, suggesting that efficacy is maintained across commonly used dosing strategies.

READ MORE: Fatigue and Objective Sleepiness Show Distinct Profiles in Patients With Obstructive Sleep Apnea

From a safety standpoint, modafinil was generally well tolerated, with most adverse events reported as mild and transient. Common side effects included headache, nausea, and insomnia, aligning with its established clinical profile. Notably, compared with traditional stimulants, modafinil is associated with lower risks of abuse, tolerance, and disruption of nocturnal sleep, factors that have contributed to its longstanding role as a first-line therapy for EDS in narcolepsy.

Despite these findings, the study underscores a critical limitation in the current evidence base. The randomized trials included in the analysis were largely conducted in the 1990s and early 2000s, with no new eligible randomized studies identified in the past decade. As the authors noted, this gap does not diminish modafinil’s clinical relevance but rather highlights the need for updated, long-term, and comparative trials to better define its role in an evolving therapeutic landscape.

Mechanistically, modafinil exerts its wake-promoting effects primarily through inhibition of dopamine reuptake via dopamine transporter binding, leading to increased extracellular dopamine in brain regions involved in wakefulness. This dopaminergic modulation is thought to underlie improvements in alertness without the high abuse potential seen with amphetamine-based stimulants.

While modafinil remains effective in reducing EDS, its impact on other core features of narcolepsy, particularly cataplexy, appears limited, often necessitating adjunctive therapies for comprehensive symptom control. As newer agents—including orexin receptor agonists and other wake-promoting therapies—continue to emerge, the positioning of modafinil within treatment algorithms may evolve.

Overall, the findings reaffirmed modafinil’s established efficacy in improving wakefulness and reducing sleepiness in narcolepsy, while emphasizing the need for modern, long-duration trials to better understand its long-term safety, durability, and comparative effectiveness in an increasingly competitive treatment landscape.

REFERENCE
1. Mann GS, Ramakrishnan M, Pakkam M, et al. An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy. Sleep Med. 2026;11:100185. doi:10.1016/j.sleepx.2026.100185